comparemela.com

Latest Breaking News On - Prnewswire natera inc - Page 1 : comparemela.com

Natera Launches Proposed Follow-On Offering

/PRNewswire/ Natera, Inc. (Nasdaq: NTRA) ("Natera"), a global leader in cell-free DNA testing, today announced the launch of a proposed follow-on public.

New yorkUnited statesSan carlosLesley bogdanowMike brophyNatera incMorgan stanleyBroadridge financial solutionsExchange commission onExchange commissionProspectus departmentClinical laboratory improvement amendmentsCorporate communicationsPrnewswire natera incSyndicate departmentMorgan stanley co

Natera Launches Proposed Follow-On Offering

/PRNewswire/ Natera, Inc. (Nasdaq: NTRA) ("Natera"), a global leader in cell-free DNA testing, today announced the launch of a proposed follow-on public.

New yorkUnited statesSan carlosLesley bogdanowMike brophyNatera incMorgan stanleyBroadridge financial solutionsExchange commission onExchange commissionProspectus departmentClinical laboratory improvement amendmentsCorporate communicationsPrnewswire natera incSyndicate departmentMorgan stanley co

Natera Reports Third Quarter 2022 Financial Results

AUSTIN, Texas, Nov. 8, 2022 /PRNewswire/ Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial result.

United statesSan carlosMike brophySteve chapmanBrian symmonsNatera incCompany annual report on formClinical laboratory improvement amendmentsPrnewswire natera incUs department of veterans affairsCorporate affairsNature medicineKidney testChief executiveQuarter ended septemberVolume summary

Natera Awarded National MRD Testing Contract by the U S Department of Veterans Affairs

/PRNewswire/ Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it was awarded a nationwide contract,.

United statesSan carlosLesley bogdanowMike brophyNatera incClinical laboratory improvement amendmentsCorporate communicationsUs department of veterans affairsPrnewswire natera incNational precision oncology programVeterans affairsSolomon moshkevichBreakthrough device designationsClin cancer

Trifecta Study Demonstrates Prospera™ Kidney dd-cfDNA Test Outperforms DSA in Predicting Antibody Mediated Rejection

/PRNewswire/ Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of the latest data from the.

United statesSan carlosMike brophyPhil halloranBrian symmonsNatera incAlberta transplant applied genomics centreDrug administrationNatera organ healthClinical laboratory improvement amendmentsPrnewswire natera incCorporate affairsProspera kidneyAlberta transplant applied genomicsMolecular microscopeDiagnostic system

vimarsana © 2020. All Rights Reserved.